CD44和CD24标记的宫颈癌细胞亚群特性

目的 考察Siha细胞系中的CD44^+/CD24⁺能否富集宫颈癌干细胞。方法 用流式细胞仪分选出CD44⁺/CD24⁺Siha细胞,用无血清悬浮培养观察成球能力、裸鼠移植瘤实验观察成瘤能力、透射电子显微镜观察辐射前后两组细胞形态变化,并通过Transwell侵袭实验比较细胞侵袭能力的差异。结果 耐放疗细胞中CD44^+/CD24⁺Siha细胞比例明显高于其在亲代Siha细胞中的比例;无血清培养CD44⁺/CD24⁺Siha细胞组可以形成致密且体积较大的细胞球,CD44^+/CD24⁺Siha细胞组致瘤时间早,成瘤率高;辐射后CD44⁺/CD24⁺Siha细胞较亲代Siha细胞更抗凋亡;CD44⁺/CD24⁺Siha细胞组的迁移细胞数明显高于亲代Siha细胞组,所有数据均具有统计学意义。结论 CD44⁺/CD24⁺Siha具备部分干细胞特性,CD44⁺/CD24⁺可能成为宫颈癌干细胞特异性表面标志物。     

免疫磁珠分选的口腔鳞状细胞癌干细胞诱导分化及成瘤活性研究

目的 探讨口腔鳞状细胞癌干细胞的诱导分化及成瘤活性。方法 采用免疫磁珠分选法从6例原代培养的口腔鳞状细胞癌细胞中分选出CD133⁺、CD44⁺细胞，以流式细胞术检测其纯度及细胞周期，并绘制CD133⁺细胞生长曲线。将分选出的细胞经诱导向成骨肪细胞及成脂肪细胞分化，将原代鳞癌细胞、分选所得的CD44⁺细胞及CD133⁺细胞进行体内成瘤实验。 结果 经免疫磁珠分选法成功获得CD44⁺细胞、CD133⁺细胞，其纯度经检测均在94%以上，且主要处于G0/G1期。CD133⁺细胞在接种后第2天进入对数期，细胞倍增时间为3.22 d。经诱导后CD44⁺、CD133⁺细胞成功分化为成骨细胞及成脂肪细胞。皮下注射后第3天可触及新生肿物，在3种细胞成瘤实验中CD133⁺细胞组瘤体体积最大，HE染色显示符合低分化口腔鳞状细胞癌病理表现。结论 免疫磁珠分选法可高效获得高纯度的口腔鳞状细胞癌干细胞。CD44⁺、CD133⁺细胞均具有较强的多向分化能力，CD133⁺细胞成瘤性较强。     

不同乳腺癌干细胞亚群的自我更新和致瘤能力差异

目的 分析原代培养乳腺癌细胞中不同乳腺癌干细胞亚群的自我更新、致瘤能力差异。方法 采用流式细胞术和免疫荧光实验,从乳腺癌原代培养细胞中分选、鉴定CD44⁺CD24^-/low、ALDH1⁺和ALDH1⁺CD44⁺CD24^-/low细胞亚群,分析各分选细胞占总肿瘤细胞的比例;通过克隆形成实验观察各组细胞的自我更新能力;通过裸鼠致瘤实验观察各组细胞的致瘤能力。结果 CD44+CD24^-/low细胞占总细胞比例的7.2%,ALDH1⁺细胞所占比例为4.6%,ALDH1⁺CD44⁺CD24^-/low细胞所占比例为1.5%。三组细胞自我更新和致瘤能力由强至弱依次为ALDH1⁺CD44⁺CD24^-/low、ALDH1⁺、CD44⁺CD24^-/low细胞,各组细胞间比较差异均存在统计学意义（P<0.05）。 结论 乳腺癌组织中CD44+CD24-/low、ALDH1⁺和ALDH1⁺CD44⁺CD24^-/low三组乳腺癌干细胞亚群之间的自我更新和致瘤能力有明显差异,ALDH1⁺CD44⁺CD24^-/low亚群细胞具有最强的自我更新和致瘤能力,提示ALDH1⁺CD44⁺CD24^-/low可能是更具有特异性的乳腺癌干细胞标志物。     

CBX7对维持肺癌干细胞表型及化疗敏感性的影响

目的:探讨色素框同源蛋白7(CBX7)对肺癌干细胞(LCSCs)表型和化疗敏感性的调节作用及部分潜在机制。方法:培养肺癌A549、NCL-H460和H1299细胞株,分选CD44⁺细胞进行后续实验。转染后,将CD44⁺LCSCs分为空白组、阴性组(转染空载体)、shCBX7(沉默CBX7表达)。细胞计数试剂盒-8(CCK-8)测定和集落形成实验分析细胞增殖能力和对化疗药物的敏感性,使用染色质免疫沉淀(ChIP)和双荧光素酶报告基因测定法验证CBX7和CD44之间的关系,Western blot检测蛋白含量。结果:成功的从A549、H460和H1299细胞中富集了CD44⁺LCSCs, CD44⁺细胞百分比为97.1%～99.5%。与CD44^-细胞相比,CD44⁺细胞中CBX7、CD44、Sox2、Nanog蛋白表达量更高(P<0.001),且CD44⁺H460细胞CBX7蛋白表达量最高(P<0.05),可用作后续沉默CBX...     

CD44+鼻咽癌细胞的干细胞生物学特性

目的从人鼻咽癌SUNE-1 5-8F细胞株中分离出CD44⁺细胞并探讨其生物学特性。方法常规培养SUNE-1 5-8F细胞,采用流式细胞学技术检测SUNE-1 5-8F细胞中CD44⁺的表达并用流式细胞仪分选CD44⁺细胞;采用四甲基偶氮唑蓝（MTT）法、克隆形成实验等检测并比较CD44⁺、CD44^-细胞在体外增殖、分化等方面的差异;并用反转录聚合酶链反应（RT-PCR）检测干细胞基因Oct4、Bmi-1的表达。结果CD44⁺细胞在鼻咽癌细胞中SUNE-1株所占的比率约为52.5%;新分选的CD44+细胞在无血清培养液和完全培养液中较CD44^-及未分选细胞均显示出较强增殖能力;RT-PCR示Bmi-1和Oct4 mRNA在CD44+细胞中的表达水平明显高于CD44^-细胞。CD44⁺和CD44-细胞在接受2Gy放射处理后,其平均克隆生成效率分别为(23.44±1.90)%和(7.78±1.17)%（P＜0.001）;CD44⁺细胞较CD44^-细胞在相同顺铂和多西他赛药物浓度下显示出更高的细胞存活率。结论CD44⁺细胞具有类肿瘤干细胞特性,可能是鼻咽癌的重要肿瘤干细胞标志之一。     

乳腺癌细胞系中肿瘤干细胞相关亚群的初步研究

目的 通过乳腺癌细胞系及其干细胞的培养,化疗药干预和流式细胞仪筛选鉴定,探讨不同乳腺癌细胞系中CD44⁺CD24^-/low细胞比例,及富集乳腺癌干细胞相关亚群的方法。方法 通过细胞培养乳腺癌细胞系MCF-7、MDA-MB-231,观察生长曲线,比较化疗药物干预下生长情况;利用流式细胞仪检测两种乳腺癌细胞系中CD44⁺CD24^-/low细胞比例;无血清悬浮培养,化疗药(多西紫杉醇、表阿霉素)干预这两种乳腺癌细胞系,观察其是否形成细胞球。结果 (1)MDA-MB-231细胞系倍增时间短,生长速率高于MCF-7细胞系;(2)MCF-7细胞系中可能存在较大比例肿瘤干细胞,其对化疗抵制,能自我更新;(3)化疗敏感性用两独立样本t检验,MCF-7细胞,差异没有统计学意义;MDA-MB-231细胞,差异有统计学意义,提示MDA-MB-231细胞系对该方案化疗较敏感;(4)无血清悬浮培养,MDA-MB-231细胞系未发现明显细胞球;MCF-7细胞系初次无血清培养约6天出现细胞球。加入化疗药筛选后两种细胞,见大部分肿瘤细胞逐渐死亡,未发现明显细胞球;(5)流式细胞仪检测,MCF-7、MDA-MB-231两种细胞系中主要是CD44⁺CD24⁺亚群和CD44^-CD24⁺亚群,CD44⁺CD24^-/low细胞比例分别2.07%和0.20%。结论 (1)MDA-MB-231细胞系增值较快,恶性度相对较高,其对TA联合化疗药物较敏感;MCF-7细胞系中可能存在少量肿瘤干细胞,对化疗抵制,能自我更新;(2)无血清培养液培养MCF-7细胞系能形成悬浮细胞球;流式细胞仪检测两种细胞系中CD44⁺CD24^-/low细胞比例小;(3)CD44⁺CD24^-/low表型可能不是乳腺癌干细胞唯一特异性的表面标志。     

肺腺癌浸润CD8+T细胞表达CD39的机制

目的：探讨肿瘤浸润CD8⁺T细胞表达CD39的可能机制。方法：通过TCGA数据库的肺腺癌(LUAD)组织及正常肺组织转录组数据分析CD39在LUAD组织和正常肺组织中的表达差异及其对患者预后的影响,分析CD39表达与T细胞浸润、激活的关系。用小鼠LUAD Lewis细胞建立小鼠皮下移植瘤模型,FCM检测淋巴结、脾脏以及移植瘤组织中CD8⁺CD39⁺T细胞。收集Lewis细胞培养上清液作为条件培养基(CCM),免疫磁珠法(MACS)分选CD8⁺T细胞、CD11b⁺细胞;在培养基中分别加入CCM、IL-6和采取非接触或接触培养方式进行培养,探索CD8⁺T细胞表达CD39的可能机制。结果：CD39在LUAD组织中呈低表达(P<0.01),其表达水平与LUAD患者OS、T细胞浸润和激活水平均呈正相关(P<0.05或P<0.001)。FCM检测结果显示,在移植瘤组织中CD8+CD39⁺T细胞的比例明显高于淋巴结及脾脏(P<...     

流式细胞仪检测恶性淋巴瘤患者外周血T细胞亚群的临床研究

目的 探讨流式细胞仪检测恶性淋巴瘤患者外周血T细胞亚群的效果及其与临床病理、肿瘤类型的关系。方法 选取我院于2014年8月-2016年9月收治的98例恶性淋巴瘤患者为研究组,同期选取98例健康体检者为对照组。应用流式细胞仪检测两组外周血T细胞亚群(CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺)并进行比较。结果 研究组CD3⁺、CD4⁺/CD8⁺水平分别为(55.63±11.25),(1.32±0.62),显著低于对照组的(68.96±12.63),(1.59±0.59),差异具有统计学意义(P＜0.05);研究组CD4⁺、CD8⁺水平(33.67±8.14),(26.02±4.67)与对照组的(34.12±8.33),(25.67±4.53)相比差异无统计学意义(P＞0.05)。霍奇金淋巴瘤、非霍奇金淋巴瘤患者CD3⁺、CD4⁺/CD8⁺水平分别为(54.63±11.36),(1.22±0.65)和(55.52±12.02),(1.34±0.71),显著低于对照组的(68.96±12.63),(1.59±0.59),差异具有统计学意义(P＜0.05);霍奇金淋巴瘤、非霍奇金淋巴瘤患者CD4⁺、CD8⁺水平分别为(33.78±8.23),(25.74±4.88)和(33.62±8.74),(26.32±4.85)与对照组的(34.12±8.33),(25.67±4.53)相比,差异无统计学意义(P＞0.05)。Ⅲ~Ⅳ期恶性淋巴瘤患者CD3⁺、CD4⁺、CD4⁺/CD8⁺水平分别为(52.66±12.47),(28.25±6.32),(1.30±0.62)明显低于对照组的(68.96±12.63),(34.12±8.33),(1.59±0.59),差异具有统计学意义(P＜0.05);Ⅰ~Ⅱ期恶性淋巴瘤患者CD3⁺水平为(58.63±11.85),显著低于对照组的(68.96±12.63),而CD8⁺水平为(29.63±3.57),显著高于对照组的(25.67±4.53),差异具有统计学意义(P＜0.05)。结论 流式细胞仪检测外周血T细胞亚群可以作为诊断恶性淋巴瘤患者的病情、分期以及免疫状态的重要手段,具有较高的应用价值。     

小鼠衰老所致“正虚”过程中免疫功能衰退表征的特点

目的：基于小鼠渐进衰老模型探讨衰老所致“正虚”的免疫功能衰退表征的特点。方法：使用不同月龄(2、6、15月龄)C57BL/6小鼠,通过流式细胞术检测并比较小鼠外周血和脾组织中T细胞、髓源性抑制细胞(MDSC)及其亚群的丰度变化。结果：外周血中T细胞亚群表型为CD3⁺CD4⁺CD44-CD62L⁺的幼稚CD4⁺T细胞(2 vs 6月龄,P=0.137;2 vs 15月龄,P=0.004;6 vs15月龄,P=0.105)和表型为CD3⁺CD8⁺CD44-CD62L⁺的幼稚CD8⁺T细胞(2 vs 6月龄,P=0.179;2 vs 15月龄,P=0.001;6 vs15月龄,P=0.015)出现与衰老有关的细胞比例降低,差异具有统计学意义。表型为CD3⁺CD4⁺CD44⁺CD62L⁺的中央记忆CD8⁺T细胞出...     

基于CD19/IgM亚群分析套细胞淋巴瘤骨髓中T细胞的构比异常

目的:研究T细胞在初诊IV期套细胞淋巴瘤(mantle cell lymphoma, MCL)骨髓单个核细胞中的差异表达。方法:首先流式检测健康供者及MCL组中CD19^-/IgM^-,CD19^-/IgM⁺,CD19⁺/IgM^-,CD19⁺/IgM⁺亚群的比例;其次检测CD45⁺CD3⁺T细胞在两组中的总比例;最后检测T细胞在两组四个亚群中的占比。结果:四个亚群在组内有极其显著的差异(P<0.000 1),两组间无统计学差异。T细胞在MCL组占(0.46±0.13)%较健康供者组(1.10±0.06)%显著减少(P=0.025 1)。四个亚群中T细胞占比在健康供者组内有极其显著的差异(P<0.000 1),而MCL组内差异消失(P=0.329 4)。T细胞在MCL组CD19^-/IgM^-亚组中占(0.02±0.01)%较...     

Homing-Associated Cell Adhesion Molecule (H-CAM/CD44) on Human CD34+ Hematopoietic Progenitor Cells

Human CD34⁺ hematopoietic progenitor cells (HPCs) express CD44 and can directly adhere to hyaluronate (HA) via CD44. Furthermore, CD44 may also be involved in the regulation of CD34⁺ HPC proliferation and development. The expression of CD44 molecules on CD34⁺ hematopoietic progenitor cells is significantly lower on bone marrow (BM) CD34⁺ cells compared with circulating CD34⁺ cells in cord blood and peripheral blood. Myeloid and erythroid progenitor cells are found predominantly in CD34⁺CD44^- cell fractions. More interestingly, CD34⁺CD44⁺ cells expressing B-lymphocyte-associated CD10 and CD19 would represent unique B-lymphocyte committed precursors in the BM, which might undergo apoptotic cell death in the early steps of B-cell differentiation.     

In vitro proliferative and differentiating characteristics of CD133(+) and CD34(+) cord blood cells in the presence of thrombopoietin (TPO) or erythropoietin (EPO). Potential implications for hematopoietic cell transplantation

We investigated the characteristics of cord blood (CD) CD133⁺ and CD34⁺ cells, by flow cytometry, clonogenic assays and assessment of the replating ability (area under the curve (AUC)) following 7-day liquid culture in the presence of early acting growth factors and either thrombopoietin (TPO) or erythropoietin (EPO). The CD34⁺ population showed a more effective proliferation in all parameters tested and TPO proved to be more effective than EPO. On the contrary, the CD133⁺ cell fraction retained and expanded more immature elements in a modest but consistent manner with either TPO or EPO. We conclude that CD133⁺ and CD34⁺ expanded cord blood cells could potentially be used in combination to overcome the shortcomings of cord blood transplantation in older children and adults.     

T-Cell Membrane CD45RA (2H4) and CD45RO (UCHL1) Determinants: I, Diverse Patterns of Expression in Mature (Post-Thymic) T-Cell Proliferations

By simultaneous two- and three-colour flow cytometry, this study analysed the expression of membrane CD45RA (2H4) and CD45RO (UCHL1) determinants by normal thymocytes (n = 5) and peripheral blood lymphocyte subpopulations (CD4⁺, n = 21; CD8⁺, n = 12; CD8^dim+, n = 12) and compared these patterns with those of T-cells from representative CD4⁺CD8^- (n = 8), CD4⁺CD8⁺ (n = 2), CD4^-CD8⁺ (n = 10) and CD4^-CD8^- (n = 1) proliferations. These comprised cases of prolymphocytic leukaemia (T-PLL, n = 5), adult T-cell leukaemia-lymphoma (ATLL, n = 2), Sezary Syndrome (SS, n = 4), chronic lymphocytic leukaemia (T-CLL, n = 4), and lymphoproliferative disease of granular lymphocytes (LDGL, n = 5). Normal thymocyte fractions, of which a mean of 85% cells co-expressed membrane CD4 and CD8, were predominantly (mean 89%) 2H4^-UCHL1⁺ with the remaining cells consisting of 2H4^intUCHL1⁺ and 2H4⁺UCHL1^- components. Further analysis showed that virtually all CDla⁺ thymocytes were UCHL1⁺ whereas the CD1a^- fraction comprised similar proportions of both UCHL1^- and UCHL1⁺ subpopulations. Similarly, normal blood CD4⁺, CD8⁺ and CD8^dim+ lymphocytes showed reciprocal CD45RA/CD45RO expression and could be phenotypically grouped into 2H4⁺UCHL1^- 2H4^intUCHL1⁺ and 2H4^-UCHL1⁺ subpopulations. Mean proportions of 48% and 68%, for CD4⁺ and CD8⁺ lymphocytes respectively, showed a composite 2H4⁺UCHL1^- phenotype, whereas the percentage of NK-associated CD8^dim+ cells with this phenotypic pattern was considerably higher (mean, 85%). Normal lymphocyte subpopulations lacking both determinants (2H4^-UCHL1^-) were only rarely noted. Comparing normal patterns of CD45RA/CD45RO expression with those of the T-cell proliferations revealed diverse and abnormal patterns of staining for 3/6 of the CD4⁺CD8^- SS and ATLL, and for 5/5 of the T-PLL (CD4⁺CD8^-, n = 2; CD4⁺CD8⁺, n = 2; and CD4^-CD8⁺, n = 1) cases studied. In contrast, the nine cases of CD4^-CD8⁺ T-CLL and LDGL all showed CD45RA/CD45RO staining patterns similar to that of normal CD8⁺/CD8^dim+ blood lymphocytes (i.e. a predominance of 2H4⁺UCHL1^- cells). Although the variant CD45RA/CD45RO pattern types of the CD4⁺ proliferations did not appear to be related to either the diagnostic category or other phenotypic characteristics, the high proportion of abnormal patterns within this case group suggests that recognition of these abnormalities may be potentially relevant to the differentiation of benign and malignant CD4⁺ proliferations and, in addition, may be of aetiological importance with respect to the diverse acquired defects in immunity commonly seen in patients with such disorders.     

T-Cell Membrane CD45RA (2H4) and CD45RO (UCHL1) Determinants: II, Aberrant HLA-ABC Expression by CD45RA and CD45RO Cell Subpopulations of Mature CD4+ T-Cell Leukaemias

Six thymocyte suspensions, 10 normal blood CD4⁺ CD8^- lymphocyte-enriched fractions and leukaemic cells from 24 patients with CD4⁺ mature T-cell lymphoid malignancy (five Sezary Syndrome, six adult T-cell leukaemia-lymphoma and 13 cases of T-cell prolymphocytic leukaemia) were examined in this study for the expression of membrane HLA-ABC by CD45RA (2H4) and CD45RO (UCHL1) subpopulations. These analyses showed that the main increase in HLA-ABC expression by normal CD4⁺ CD8^- blood lymphocytes (mean 490 to 760 FITC units) paralleled the loss of membrane 2H4 whilst the acquisition of UCHL1 was not associated with any significant change in HLA-ABC staining intensity. The sequence of 2H4 differentiation by normal thymocytes, based on the observed increasing levels of HLA-ABC staining intensity appeared to be (a) CD1a ⁺ 2H4^- UCHL1⁺ (25 HLA-ABC fluorescent units), (b)CD1a^-2H4^intUCHL1⁺ (134 units), and (c) CD 1a^- 2H4 ⁺ UCHL1 ^- (197 units). Quantitative estimates of membrane HLA-ABC expression by leukaemic T-cells revealed marked heterogeneity between individual cases irrespective of diagnostic subgroup. Based on the lower observed limits for normal CD4⁺ 2H4⁺ (318 units) and CD4 ⁺ 2H4^- (478 units) fractions, 14% and 38% respectively of the leukaemic 2H4⁺ and 2H4^- components examined showed reduced HLA-ABC expression. Two cases showed very low membrane HLA-ABC levels that were within the range observed for normal CD1a^- thymocytes. In contrast, HLA-ABC staining intensities exceeding that of corresponding normal CD4⁺ 2H4⁺ (710 units) and CD4⁺ 2H4^- (1286 units) subpopulations were seen in a high proportion (65%) of leukaemic 2H4 ⁺ components, with only 14% of 2H4^- fractions showing raised levels and, in two cases, these staining intensities exceeded three times the normal observed limits. In addition to the quantitative differences in HLA-ABC expression, a remarkably consistent (81% of evaluable cases) feature of the leukaemic T-cells was that the 2H4^-UCHL1⁺ subpopulation in CD4⁺ malignancies had a lower HLA-ABC level than the 2H4⁺UCHL1 subpopulation. This was in marked contrast to normal post-thymic T-cells where increasing HLA-ABC expression was seen with increasing UCHL1 (or decreasing 2H4) staining. These results suggest that leukaemic T-cells have an aberrant intra-thymic and post-thymic sequence of 2H4/UCHL1 expression which has become 'uncoupled' from CD1a/HLA-ABC expression.     

Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma

Objective: To study the frequency of the CD4⁺CD25⁺ regulatory T cells (Tregs) in the patients with ovarian carcinoma and its possible mechanism. Methods: The percentages of CD4⁺CD25⁺ Tregs in the peripheral blood lymphocytes (PBLs), tumor infiltrating lymphocytes (TILs) and tumor associated lymphocytes (TALs) from 13 patients with ovarian carcinoma and in the PBLs from 14 healthy women were determined by flow cytometry. The expression of CD69 on CD4⁺PBLs from the patients was detected. PBLs from healthy women were cultured in complete RPMI 1640 containing the supernatant from SKOV3 cell line with or without PHA (phytohemagglutinin) stimulation for 72 hours, then the percentage of CD4⁺CD25⁺ T cells was detected. Results: CD4⁺CD25⁺ Tregs in the PBLs from patients with ovarian carcinoma were significantly increased compared with those from the control. The percentage of CD4⁺CD25⁺ Tregs in TILs was higher than that in PBLs and TALs from the patients, but not significantly. The expression of CD69 on CD4⁺PBLs from the patients was negative. The percentages of CD4⁺CD25⁺ T cells in PBLs cultured with SKOV3 supernatant elevated significantly compared with those without supernatant whether PHA was added or not (P = 0.001 and 0.001, respectively). Conclusion: There is an increasing of the proportion of CD4⁺CD25⁺ Tregs in PBLs, TILs and TALs of the patients with ovarian carcinoma, which probably results from up-regulation of soluble factor secreted by ovarian carcinoma cells.     

CD15及CD133在高、低级别胶质瘤中的表达及意义

目的探讨CD15在胶质瘤的表达及分布特征,与目前公认的脑肿瘤干细胞标志物CD133作对照,并探讨两者相关性。方法采用免疫组织化学法检测80例胶质瘤组织（高级别39例,低级别41例）CD15和CD133的表达。用Image-Pro Plus 6.0图像分析处理软件计算CD15和CD133阳性细胞积分光密度值（IOD）。结果CD15与CD133在高、低级别的胶质瘤均有表达。CD15及CD133阳性细胞数以及壁龛随胶质瘤病理级别增高而增多。在高、低级别胶质瘤中CD15⁺细胞与CD133⁺细胞IOD值差异均有统计学意义（z=－3.432,P=0.001;z=－4.192,P=0.000）;CD15⁺细胞与CD133⁺细胞IOD值呈显著正相关（r=0.535,P=0.000）;CD133还表达于含有肥胖细胞成分的胶质瘤肥胖细胞中,并可见CD133+血管。结论CD15及CD133阳性细胞数以及壁龛随胶质瘤病理级别增高而增多。CD15及CD133表达成正相关关系。含有肥胖细胞成分的胶质瘤中大量肥胖细胞CD133阳性,与其不良临床预后相符。关键词：     

CD44+CD24-/low在基底样乳腺癌中过表达与其恶性预后的相关性研究

目的探讨乳腺癌干细胞样标志物CD44⁺CD24^-/low在基底样乳腺癌(basal-like breast carcinoma, BLBC)中过表达与BLBC恶性预后的相关性。方法 在乳腺癌基因表达分型的基础上, 根据雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(Her-2)免疫表型的表达选取乳腺癌组织四组:管腔A组、管腔B/C组、Her-2高表达组及三阴性组;对三阴性组检测CK5/6、EGFR, 分为正常乳腺样型和BLBC型两组;对上述5组进行免疫组化Envision法染色, 选用抗体为CD44、CD24, 观察CD44⁺CD24^-/low表型表达并比较BLBC组与其它各组的差异。结果 (1)三阴性组共60例, CK5/6和或EGFR阳性者41例(68.3%), 确定为BLBC;CK5/6、EGFR阴性者19例(31.7%), 确定为正常乳腺样组;(2)CD44⁺CD24^-/low表型在BLBC组中占78.0%(32/41), 相对于管腔A组37.9%(11/29)、管腔B组25.9%(7/27)、Her-2高表达组17.2%(5/29)、正常乳腺样组26.3%(5/21), 表达增高并具有显著性(P＜0.05);(3)所有150例乳腺癌中(可评价145例)具有CD44⁺CD24^-/low免疫表型者其Ki-67指数增高相对于非CD44⁺CD24^-/low表型具有统计学差异(P＜0.001)。结论 BLBC型乳腺癌表达乳腺癌干细胞样标志物CD44⁺CD24^-/low显著高于其它各型乳腺癌, CD44⁺CD24^-/low与BLBC独特的恶性生物学行为相关。